These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 34287335)
1. Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review. Maini K; Gould H; Hicks J; Iqbal F; Patterson J; Edinoff AN; Cornett EM; Kaye AM; Viswanath O; Urits I; Kaye AD Neurol Int; 2021 Jul; 13(3):279-296. PubMed ID: 34287335 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071 [TBL] [Abstract][Full Text] [Related]
3. Aripiprazole Lauroxil: A Review in Schizophrenia. Frampton JE Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572 [TBL] [Abstract][Full Text] [Related]
4. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572 [TBL] [Abstract][Full Text] [Related]
5. Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia. Maini K; Hollier JW; Gould H; Bollich V; John LaForge J; Cornett EM; Edinoff AN; Kaye AM; Kaye AD Health Psychol Res; 2021; 9(1):24932. PubMed ID: 34746489 [TBL] [Abstract][Full Text] [Related]
6. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240 [TBL] [Abstract][Full Text] [Related]
9. Aripiprazole Lauroxil NanoCrystal Ehret MJ; Davis E; Luttrell SE; Clark C Clin Schizophr Relat Psychoses; 2018; 12(2):92-96. PubMed ID: 30040476 [TBL] [Abstract][Full Text] [Related]
10. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202 [TBL] [Abstract][Full Text] [Related]
11. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. Risinger R; Hard M; Weiden PJ Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337 [TBL] [Abstract][Full Text] [Related]
12. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. Nasrallah HA; Newcomer JW; Risinger R; Du Y; Zummo J; Bose A; Stankovic S; Silverman BL; Ehrich EW J Clin Psychiatry; 2016 Nov; 77(11):1519-1525. PubMed ID: 27574838 [TBL] [Abstract][Full Text] [Related]
13. A safety evaluation of aripiprazole in the treatment of schizophrenia. Preda A; Shapiro BB Expert Opin Drug Saf; 2020 Dec; 19(12):1529-1538. PubMed ID: 33064050 [TBL] [Abstract][Full Text] [Related]
14. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil. Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338 [TBL] [Abstract][Full Text] [Related]
15. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Citrome L Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020 [TBL] [Abstract][Full Text] [Related]
16. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. Weiden PJ; Du Y; Liu CC; Stanford AD CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057 [TBL] [Abstract][Full Text] [Related]
17. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Swainston Harrison T; Perry CM Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226 [TBL] [Abstract][Full Text] [Related]
19. Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm. Citrome L; Du Y; Weiden PJ Neuropsychiatr Dis Treat; 2019; 15():2639-2646. PubMed ID: 31686823 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]